Reduced Risk of Breast Cancer Recurrence in Patients Using ACE Inhibitors, ARBs, and/or Statins

• DOI: 10.3109/07357907.2011.616252
• Publication Date: 2011-09-21T09:38:04Z
• Authors: Young Kwang Chae; Matias E. Valsecchi; Jongoh Kim; Anabella Lucca Bi...; Danai Khemasuwan; Ajit Desai; William Tester
• Keywords: Univariate analysis; Angiotensin Receptor Blockers; Lower risk

Background: Epidemiologic and biochemical evidence suggest a role of statins angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) as anti-neoplastic agents. This study was designed to evaluate the association between use these agents risk breast cancer recurrence. Methods: We reviewed medical records patients treated for stage II/III 1999 2005. Statin ACE-inhibitors/ARB users were defined who took medications at least 6 months in no disease (NED) after initial diagnosis. The primary outcome disease-free survival secondary overall survival. Kaplan–Meier Cox proportional hazard models used. Results: A total 703 included. median maximal follow up 55 118 months, respectively. 168 used ACE-inhibitors/ARBs, 156 statins, 81 both. Univariate analysis showed significant reduction recurrence among ACE-inhibitors/ARBs (hazard ratio (HR) = 0.57; 95% CI: 0.37–0.89; p .013) (HR 0.43; 0.26–0.70; < .001). After adjusting multiple variables, 0.49; 0.31–0.76; .002) 0.40; 0.24–0.67; .001) remained an additive effect found on those both drugs 0.30 0.15–0.61; No regarding Conclusions: combination all associated with reduced observation should prompt further exploration.